MedTrace Logo

Recurrence Risk Evaluation by 21-gene Detection

NCT03841266 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 220

Last updated 2019-02-15

No results posted yet for this study

Summary

Breast cancer patients with early breast cancer were enrolled according to the inclusion criteria. Baseline characteristics were recorded from medical record system. Recurrence score were obtained by 21-gene detection kits from different biological companies. Relationship between recurrence score and the prognosis was explored. Meanwhile, the investigators analyzed the consistency of the results obtained from various 21-gene test kits and immunohistochemistry detection.

Conditions

  • Relationship and Consistency Analysis

Interventions

DIAGNOSTIC_TEST

recurrence risk evaluation

Recurrence score were obtained by 21-gene detection kits from different biological companies. The expression of ER, PR, and Her-2 were also detected by IHC.

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2019-01-20
Completion
2019-02-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03841266 on ClinicalTrials.gov